Cipla has acquired a patented anti-infective drug Elores from Venus Remedies Ltd. The product is used for the treatment of life-threatening infections caused by certain bacteria. The company feels that the acquisition would help to strengthen its presence in the branded Indian critical-care space. The company’s market share in the anti-infective space has shrunk marginally in the last few years – from 23.4 percent as on August 2017 to 21 percent as on this year, as per AIOCD AWACS data. Elores is a novel combination, which is used as an antibiotic-resistance breaker (ARB). It basically helps to preserve the efficacy of an antibiotic, using appropriate ARBs. It was launched across tertiary care hospitals in the country in 2013 after the Drug Controller General of India (DCG) approved it.
Anti-microbial resistance (AMR) has emerged as a critical threat to public health. At the present rate, it is estimated that as many as 10 million individuals worldwide could die annually from complications related to AMR. India carries one of the largest burdens of drug-resistant pathogens worldwide.